Notably, USP47 shows promise as a target for overcoming TKI resistance in chronic myelogenous leukemia (CML) and is implicated in protein aggregation and clearance pathways related to neurodevelopment and neurodegenerative diseases. Here, USP47 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.